IGF-1 LR3
← Back to LibraryCompound Profile
IGF-1 LR3 is reviewed here for growth-hormone signaling and recovery context.
Research Summary
Published literature searches and source-listed protocols
Growth-hormone signaling, Recovery, Body composition
Target context: IGF-1
Limited or not established.
Treat protocols as educational examples unless stronger sources are listed.
Route(s)
Subcutaneous
Typical dose
33mcg
Dosing window
Post-Workout
Receptor / target
IGF-1
Properties
Not listed
Pre-mixed
No
How IGF-1 LR3 works in the body
IGF-1 LR3 is a long-acting analog of insulin-like growth factor 1.
Muscle (Mechanistic)
IGF-1 signals muscle cells directly to grow and repair. Used in research and performance contexts; human safety data as a supplement is limited.
Educational only, not medical advice. Labels describe the type of research behind each area, not a recommendation.
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 33mcg daily | 1x/day, 7 days per week. Dose immediately post-workout (within 30 mins) with carbs and protein. |
| Week 2 | 50mcg daily | 1x/day, 7 days per week. Avoid taking at bedtime or while fasted. |
| Weeks 3-4 | 75mcg daily | 1x/day, 7 days per week. Ensure adequate calories/protein are consumed. |
| Weeks 5-8 | 100mcg daily | 1x/day, 7 days per week. Maximum recommended dosage phase. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative: Bilateral IM
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 50mcg split (25mcg per side) | Administered intramuscularly into the trained muscle group (e.g., left and right bicep) immediately post-workout. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | No approved FDA label was identified for this entry; evidence should be treated as literature context rather than validated dosing guidance. |
|---|---|
| Where studied | Studied around pituitary GH signaling, IGF-1 response, body-composition endpoints, growth-hormone deficiency models, or discontinued anabolic programs depending on the compound. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: IGF-1. Route(s): Subcutaneous. Dosing window on page: Post-Workout. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard. |
Source-linked findings
- GH-axis compounds are best interpreted through pituitary physiology, IGF-1 response, pulse timing, and metabolic adverse effects rather than dose escalation alone.
- Evidence strength ranges from approved labels for specific agents to sparse or discontinued development programs for research peptides.
- No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Week 1, 33mcg daily; Alternative: Bilateral IM: Weeks 1-8, 50mcg split (25mcg per side).
- Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard.
- Monitor IGF-1 response, fasting glucose/A1c, edema, carpal-tunnel symptoms, blood pressure, sleep apnea, and malignancy history.
Selected medical sources
Independent evidence
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Active cancer: IGF-1 is a potent mitogen; direct IGF-1 receptor activation accelerates proliferation of malignant cells.
- History of malignancy: especially hormone-sensitive cancers; IGF-1 receptor signaling drives tumor growth in breast, prostate, and colorectal cancers.
- Hypoglycemia or hypoglycemia unawareness: acute hypoglycemia is the primary risk; IGF-1 receptor activity mimics insulin; never administer fasted.
- Diabetic ketoacidosis.
- Type 1 or insulin-dependent diabetes: IGF-1's insulin-like activity requires careful glycemic management.
- Concurrent use with insulin: severe additive hypoglycemia risk; extreme caution required.
- Concurrent administration without food: administration without concurrent carbohydrates and protein is contraindicated; hypoglycemia risk is immediate.
- Pre-existing visceral organ enlargement: IGF-1 at high doses drives growth in all IGF-1 receptor-expressing tissues, including intestinal epithelium and visceral organs.
- Active acromegaly: additive IGF-1 receptor stimulation in a state of existing IGF-1 excess.
- Pregnancy: IGF-1 analog activity not established in pregnancy; potential fetal risk.
- Breastfeeding: safety not established.
- Known hypersensitivity to IGF-1 LR3 or excipients.
- Pediatric use: safety and efficacy not established; open growth plates in children risk inappropriate and disproportionate skeletal growth.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Severe hypoglycemia: the most critical adverse effect; direct insulin-like glucose uptake via IGF-1 receptor activation; onset typically 30-60 minutes post-injection; more pronounced with fasted administration; always administer with carbohydrates present.
- Intestinal growth and gut hypertrophy: with abused long-term or excessive dosing, IGF-1 receptor stimulation in gastrointestinal epithelium can cause measurable organ enlargement; this is the primary long-term misuse risk.
- Visceral organ growth: liver, spleen, kidneys; IGF-1 receptor is expressed in all visceral organs; supraphysiologic IGF-1 exposure over extended periods may drive size increases.
- Localized swelling at injection site: tissue response to subcutaneous or intramuscular injection.
- Edema: IGF-1-mediated sodium and fluid retention.
- Jaw tightening or facial growth (at high doses/extended abuse): IGF-1 receptors in craniofacial tissues; acromegalic-type effects at very high doses.
- Joint pain: GH/IGF-1 axis-mediated periarticular fluid.
- Headache.
- Fatigue: transient post-injection.
- Nausea: dose-dependent.
- Increased appetite: orexigenic effect of IGF-1 receptor activity.
- Tingling or numbness in extremities: insulin-like effects and fluid shifts.
- Carpal tunnel syndrome risk: with extended high-dose use.
- Downregulation of endogenous GH production: negative feedback from elevated IGF-1 on hypothalamic-pituitary axis; natural GH production suppressed during and after long cycles.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.